Analysing targets and drugs to populate the GToP database
-
Upload
chris-southan -
Category
Documents
-
view
189 -
download
0
description
Transcript of Analysing targets and drugs to populate the GToP database
![Page 1: Analysing targets and drugs to populate the GToP database](https://reader035.fdocuments.net/reader035/viewer/2022062513/554e7bd4b4c9054a698b5157/html5/thumbnails/1.jpg)
1
www.guidetopharmacology.org
Analysing targets and drugs to populate the GToP database
Chris Southan, presented at the University of Capetown, July 2014
IUPHAR/BPS Guide to PHARMACOLOGY Web portal Group, Centre for Integrative Physiology, School of Biomedical Sciences, University of Edinburgh,
Hugh Robson Building, Edinburgh, EH8 9XD, UK. [email protected]
![Page 2: Analysing targets and drugs to populate the GToP database](https://reader035.fdocuments.net/reader035/viewer/2022062513/554e7bd4b4c9054a698b5157/html5/thumbnails/2.jpg)
2
Outline
• Target considerations• Target numbers in databases and the literature• The GToPdb approach to primary target mapping• Target proteins and Gene Ontology comparisons• The GToPdb approved target function distribution• Drug consensus sets• Conclusions
![Page 3: Analysing targets and drugs to populate the GToP database](https://reader035.fdocuments.net/reader035/viewer/2022062513/554e7bd4b4c9054a698b5157/html5/thumbnails/3.jpg)
3
Target considerations
• The capture (in GToPdb and other sources) of the data-supported molecular mechanisms for a drug has crucial pharmacological, bioinformatics and cheminformatics utility
• The concept of “primary target” postulates a causal, necessary and sufficient link between a direct drug binding and clinical efficacy
• Polypharmacology (multiple efficacy targets) is important but difficult to prove experimentally or clinically
• The in vitro kinetic parameters and cross-reactivity for the same mechanisms are different and experimentally variable
• Verification of target engagement and residence time in vivo is rare • Many proteins in listings are not actual drug targets ; (e.g. albumin,
trypsin, HERG, APP, P450s) or were not (e.g. ACE2, BACE2)• Phenotypic screening may be on the ascendance, but deconvolution
to mechanism of action remains important
![Page 4: Analysing targets and drugs to populate the GToP database](https://reader035.fdocuments.net/reader035/viewer/2022062513/554e7bd4b4c9054a698b5157/html5/thumbnails/4.jpg)
4
The spread of target numbers
![Page 5: Analysing targets and drugs to populate the GToP database](https://reader035.fdocuments.net/reader035/viewer/2022062513/554e7bd4b4c9054a698b5157/html5/thumbnails/5.jpg)
5
Literature and patent target growth
![Page 6: Analysing targets and drugs to populate the GToP database](https://reader035.fdocuments.net/reader035/viewer/2022062513/554e7bd4b4c9054a698b5157/html5/thumbnails/6.jpg)
6
Slow growth in new small-molecule targets
![Page 7: Analysing targets and drugs to populate the GToP database](https://reader035.fdocuments.net/reader035/viewer/2022062513/554e7bd4b4c9054a698b5157/html5/thumbnails/7.jpg)
7
The GToPdb approach to target mapping
• Focus on minimal, rather than maximal relationship capture, to produce a concise “drugged genome”
• Read the papers to resolve the mechanisms• Stringent mapping by citable data (e.g. Kd, Ki, IC50)• Mask nutraceuticals/metabolites/hormones from these mappings• Use consensus sets (human UniProt/Swiss-Prot IDs) to map “out”
to drugs• Use consensus drug structures (PubChem CIDs) to map “in” to
targets• Reduce complex subunit mapping to direct interactions• Avoid matrix screening results for primary mappings• Pragmatically flexible i.e. can include dual inhibitors, proven
secondary targets, non-human mappings or unknown mechanisms
![Page 8: Analysing targets and drugs to populate the GToP database](https://reader035.fdocuments.net/reader035/viewer/2022062513/554e7bd4b4c9054a698b5157/html5/thumbnails/8.jpg)
8
Primary target annotation
![Page 9: Analysing targets and drugs to populate the GToP database](https://reader035.fdocuments.net/reader035/viewer/2022062513/554e7bd4b4c9054a698b5157/html5/thumbnails/9.jpg)
9
Selecting a primary target from a complex
PSEN1
Gamma secretase
![Page 10: Analysing targets and drugs to populate the GToP database](https://reader035.fdocuments.net/reader035/viewer/2022062513/554e7bd4b4c9054a698b5157/html5/thumbnails/10.jpg)
10
Comparing target sets in the protein database
![Page 11: Analysing targets and drugs to populate the GToP database](https://reader035.fdocuments.net/reader035/viewer/2022062513/554e7bd4b4c9054a698b5157/html5/thumbnails/11.jpg)
Intersects and differences between target sets
11
Selects made from June 2014 UniProt(no species filter)
ChEMBLDrugB = DrugBankBdb = BindingDBGTP = Guide to PHARMACOLOGY
![Page 12: Analysing targets and drugs to populate the GToP database](https://reader035.fdocuments.net/reader035/viewer/2022062513/554e7bd4b4c9054a698b5157/html5/thumbnails/12.jpg)
12
Gene Ontology for intersects and differentials
![Page 13: Analysing targets and drugs to populate the GToP database](https://reader035.fdocuments.net/reader035/viewer/2022062513/554e7bd4b4c9054a698b5157/html5/thumbnails/13.jpg)
13
GToPdb targets for approved drugs
281 primary targets of approved drugs501 protein mappings of approved drugs
354 UniProt intersect
![Page 14: Analysing targets and drugs to populate the GToP database](https://reader035.fdocuments.net/reader035/viewer/2022062513/554e7bd4b4c9054a698b5157/html5/thumbnails/14.jpg)
14
GToPdb approved targets: class and pathway splits
![Page 15: Analysing targets and drugs to populate the GToP database](https://reader035.fdocuments.net/reader035/viewer/2022062513/554e7bd4b4c9054a698b5157/html5/thumbnails/15.jpg)
15
Getting to the real drugs: developing a consensus triage
![Page 16: Analysing targets and drugs to populate the GToP database](https://reader035.fdocuments.net/reader035/viewer/2022062513/554e7bd4b4c9054a698b5157/html5/thumbnails/16.jpg)
16
Issues for approved drug structure discordance
• Our analysis is being extended to include additional drug sources and we have constituted a new NC-IUPHAR expert subcommittee to support us in resolving challenging cases
• We have introduced new relationships such as drug <-> prodrug and active metabolites
• Representational discordance between the same canonical drugs in documents and databases is a serious issue in pharmacology, medicinal chemistry and cheminformatics
• Contributory factors include naming inconsistencies, salt permutations,
stereo forms, tautomerism, legacy dominance of PDF images and errors
• Definitive sets will require not only more inter-source collaboration for standardisation (including wider use of InChI) but also that regulatory bodies and pharmaceutical companies directly engage with provenancing public database structures for clinically used drugs
![Page 17: Analysing targets and drugs to populate the GToP database](https://reader035.fdocuments.net/reader035/viewer/2022062513/554e7bd4b4c9054a698b5157/html5/thumbnails/17.jpg)
17
Conclusions
• Published and database target numbers diverge mainly because of different curatorial selectivity
• Current inner limit ~ 300, outer limit ~ 2000 • New mechanisms for new approved drugs are low • GToPdb uses consensus lists as starting points for curation • Utilities of our minimal primary target set:
– Validated mechanisms– Defining the core drugged genome and pocketome– Use as “small (but perfectly formed) data” to underpin “big (noisy)
data”
• Drug structure discordance in global databases is a serious issue
![Page 18: Analysing targets and drugs to populate the GToP database](https://reader035.fdocuments.net/reader035/viewer/2022062513/554e7bd4b4c9054a698b5157/html5/thumbnails/18.jpg)
Acknowledgments and
referencesQuestions ?
18